Lataa...
Sipuleucel-T: harbinger of a new age of therapeutics for prostate cancer
Sipuleucel-T (Provenge) is the first therapeutic cancer vaccine approved by the U.S. FDA. The approval heralds the long-awaited promise of improved patient survival with minimal toxicity by therapies designed to generate an active, specific anticancer immune response. The development of this first-i...
Tallennettuna:
| Päätekijät: | , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2011
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3460263/ https://ncbi.nlm.nih.gov/pubmed/21332262 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1586/erv.10.173 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|